Last checked at 27 Sep 2021 07:00
Shield Therapeutics plc
("Shield or the "Company" or the "Group")
Jose A. Menoyo MD Appointed as Chief Medical Officer
London, UK, 27 September 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/ Feraccru® (ferric maltol), announces that Jose A. Menoyo, M.D., is joining Shield's Senior Executive Team as Vice President and Chief Medical Officer with immediate effect.
Jose A. Menoyo, M.D.
Prior to joining Shield, Dr. Menoyo served as Head of US Medical Affairs at Alexion Pharmaceuticals, Inc. ("Alexion"), a publicly traded biotechnology company, acquired by AstraZeneca in July 2021. In this role, Dr. Menoyo led the Medical Affairs and Health Outcomes and Research teams that supported several launches in the rare disease area. Prior to his role at Alexion, Dr. Menoyo was the Sr. Vice-President of Clinical Development and Medical Affairs for ZS Pharma, which was eventually acquired by AstraZeneca. Previous biopharmaceutical experience includes leadership roles at Amgen, Genzyme, and Sanofi.
Dr. Menoyo completed his Internal Medicine and Nephrology Fellowship at Hahnemann University Hospital and Medical College of Pennsylvania and will be reporting to Greg Madison, CEO.
Greg Madison, CEO of Shield, said: "Dr. Menoyo brings more than 25 years of experience in medical affairs, drug development, and regulatory leadership across both large and small publicly traded biopharmaceutical companies which includes successful drug global launches and commercialisation support. Dr. Menoyo has extensive US and Global experience in building and leading high performing teams and his particular and proven expertise in establishing and executing Medical Affairs strategies will be extremely valuable to Shield for the launch of Accrufer in the US.
The Company also confirms that further to the announcement issued on 28 May 2021, Tim Watts will resign from the Board with effect from 30 September 2021 and no longer have any role with the Group from that date.
"I would like to thank Tim for his crucial role in bringing Shield to the point at which Accrufer can be launched in the US and wish him well for the future. "
For further information, please contact:
Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
Greg Madison (CEO) Hans-Peter Rudolf, CFO | |||
Peel Hunt LLP - Nominated Adviser & Joint Broker | +44 (0) 20 7148 8900 | ||
James Steel / Christopher Golden | |||
finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
Geoff Nash / Alice Lane/ George Dollemore | |||
|
| ||
Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
Paul McManus / Lianne Cawthorne/ Alice Woodings | or shield@walbrookpr.com | ||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx